Cite
A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: Crossover comparisons with intravenous paclitaxel.
MLA
Hong, Yong, et al. “A Phase I Study of DHP107, a Mucoadhesive Lipid Form of Oral Paclitaxel, in Patients with Advanced Solid Tumors: Crossover Comparisons with Intravenous Paclitaxel.” Investigational New Drugs, vol. 31, no. 3, June 2013, pp. 616–22. EBSCOhost, https://doi.org/10.1007/s10637-012-9841-7.
APA
Hong, Y., Kim, K., Lim, H.-S., Bae, K.-S., Ryu, M.-H., Lee, J.-L., Chang, H., Kang, Y.-K., Kim, H., & Kim, T. (2013). A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: Crossover comparisons with intravenous paclitaxel. Investigational New Drugs, 31(3), 616–622. https://doi.org/10.1007/s10637-012-9841-7
Chicago
Hong, Yong, Kyu-pyo Kim, Hyeong-Seok Lim, Kyun-Seop Bae, Min-Hee Ryu, Jae-Lyun Lee, Heung Chang, Yoon-Koo Kang, Hyeyoun Kim, and Tae Kim. 2013. “A Phase I Study of DHP107, a Mucoadhesive Lipid Form of Oral Paclitaxel, in Patients with Advanced Solid Tumors: Crossover Comparisons with Intravenous Paclitaxel.” Investigational New Drugs 31 (3): 616–22. doi:10.1007/s10637-012-9841-7.